APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeted PSMA Radionuclide Drug Conjugates

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Targeted PSMA Radionuclide Drug Conjugates Industry Growth and Trends Forecast to 2032

28 December 202591 pages

Choose your research edition.

Industry ResearchTargeted PSMA Radionuclide Drug Conjugates Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeted PSMA Radionuclide Drug Conjugates Industry Growth and Trends Forecast to 203291 pages · $3,450 USDMarket StructureGlobal Targeted PSMA Radionuclide Drug Conjugates Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeted PSMA Radionuclide Drug Conjugates Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeted PSMA Radionuclide Drug Conjugates Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Targeted PSMA Radionuclide Drug Conjugates market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Targeted PSMA Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Targeted PSMA Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeted PSMA Radionuclide Drug Conjugates is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Targeted PSMA Radionuclide Drug Conjugates include Grand Pharmaceutical, Novartis, University of California, Telix Pharmaceutical and Lantheus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Targeted PSMA Radionuclide Drug Conjugates market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Targeted PSMA Radionuclide Drug Conjugates market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Targeted PSMA Radionuclide Drug Conjugates market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Targeted PSMA Radionuclide Drug Conjugates.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Targeted PSMA Radionuclide Drug Conjugates market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Targeted PSMA Radionuclide Drug Conjugates Market by Company

Grand Pharmaceutical

Novartis

University of California

Telix Pharmaceutical

Lantheus

Targeted PSMA Radionuclide Drug Conjugates Segment by Type

Diagnostic

Therapeutic

Targeted PSMA Radionuclide Drug Conjugates Segment by Application

Hospital

Specialist Clinic

Other

Targeted PSMA Radionuclide Drug Conjugates Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted PSMA Radionuclide Drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeted PSMA Radionuclide Drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted PSMA Radionuclide Drug Conjugates.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Targeted PSMA Radionuclide Drug Conjugates manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Targeted PSMA Radionuclide Drug Conjugates in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Diagnostic Table 2. Major Company of Therapeutic Table 3. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (K Units) Table 5. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Type (2021-2026) Table 6. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (US$ Million) Table 7. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Type (2021-2026) Table 8. Global Targeted PSMA Radionuclide Drug Conjugates Price by Type (2021-2026) & (US$/Unit) Table 9. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2027-2032) & (K Units) Table 10. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Type (2027-2032) Table 11. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2027-2032) & (US$ Million) Table 12. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Type (2027-2032) Table 13. Global Targeted PSMA Radionuclide Drug Conjugates Price by Type (2027-2032) & (US$/Unit) Table 14. North America Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (K Units) Table 15. North America Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (K Units) Table 17. Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (K Units) Table 21. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Type (2021-2026) & (US$ Million) Table 24. Targeted PSMA Radionuclide Drug Conjugates Industry Trends Table 25. Targeted PSMA Radionuclide Drug Conjugates Industry Drivers Table 26. Targeted PSMA Radionuclide Drug Conjugates Industry Opportunities and Challenges Table 27. Targeted PSMA Radionuclide Drug Conjugates Industry Restraints Table 28. Global Targeted PSMA Radionuclide Drug Conjugates Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Targeted PSMA Radionuclide Drug Conjugates Revenue Market Share by Company (2021-2026) Table 30. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Company (2021-2026) & (K Units) Table 31. Global Targeted PSMA Radionuclide Drug Conjugates Sales Share by Company (2021-2026) Table 32. Global Targeted PSMA Radionuclide Drug Conjugates Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Targeted PSMA Radionuclide Drug Conjugates Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Targeted PSMA Radionuclide Drug Conjugates Major Company Production Sites and Headquarters Table 35. Global Targeted PSMA Radionuclide Drug Conjugates Company, Product Type & Application Table 36. Global Targeted PSMA Radionuclide Drug Conjugates Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Targeted PSMA Radionuclide Drug Conjugates by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2021-2026) & (K Units) Table 41. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Region (2021-2026) Table 42. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2021-2026) & (US$ Million) Table 43. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Region (2021-2026) Table 44. Global Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2027-2032) & (K Units) Table 46. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Region (2027-2032) Table 47. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Region (2027-2032) & (US$ Million) Table 48. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Region (2027-2032) Table 49. Global Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (K Units) Table 52. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Application (2021-2026) Table 53. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (US$ Million) Table 54. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Application (2021-2026) Table 55. Global Targeted PSMA Radionuclide Drug Conjugates Price by Application (2021-2026) & (US$/Unit) Table 56. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2027-2032) & (K Units) Table 57. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Application (2027-2032) Table 58. Global Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2027-2032) & (US$ Million) Table 59. Global Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Application (2027-2032) Table 60. Global Targeted PSMA Radionuclide Drug Conjugates Price by Application (2027-2032) & (US$/Unit) Table 61. North America Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (K Units) Table 62. North America Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (K Units) Table 64. Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (K Units) Table 68. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Application (2021-2026) & (US$ Million) Table 71. Grand Pharmaceutical Company Information Table 72. Grand Pharmaceutical Business Overview Table 73. Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 75. Grand Pharmaceutical Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Novartis Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 80. Novartis Recent Development Table 81. University of California Company Information Table 82. University of California Business Overview Table 83. University of California Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. University of California Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 85. University of California Recent Development Table 86. Telix Pharmaceutical Company Information Table 87. Telix Pharmaceutical Business Overview Table 88. Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 90. Telix Pharmaceutical Recent Development Table 91. Lantheus Company Information Table 92. Lantheus Business Overview Table 93. Lantheus Targeted PSMA Radionuclide Drug Conjugates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Portfolio Table 95. Lantheus Recent Development Table 96. North America Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 97. North America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 98. North America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2026) Table 99. North America Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032) & (K Units) Table 100. North America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share Forecast by Country (2027-2032) Table 101. North America Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 102. North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026) & (US$ Million) Table 103. North America Targeted PSMA Radionuclide Drug Conjugates Market Share by Country (2021-2026) Table 104. North America Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032) & (US$ Million) Table 105. North America Targeted PSMA Radionuclide Drug Conjugates Market Share Forecast by Country (2027-2032) Table 106. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 107. Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 108. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2026) Table 109. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032) & (K Units) Table 110. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Market Share Forecast by Country (2027-2032) Table 111. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 112. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026) & (US$ Million) Table 113. Europe Targeted PSMA Radionuclide Drug Conjugates Market Share by Country (2021-2026) Table 114. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032) & (US$ Million) Table 115. Europe Targeted PSMA Radionuclide Drug Conjugates Market Share Forecast by Country (2027-2032) Table 116. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 117. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 118. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2026) Table 119. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032) & (K Units) Table 120. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Market Share Forecast by Country (2027-2032) Table 121. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026) & (US$ Million) Table 123. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Share by Country (2021-2026) Table 124. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Share Forecast by Country (2027-2032) Table 126. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 127. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 128. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2026) Table 129. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032) & (K Units) Table 130. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share Forecast by Country (2027-2032) Table 131. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026) & (US$ Million) Table 133. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Share by Country (2021-2026) Table 134. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Share Forecast by Country (2027-2032) Table 136. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026) & (K Units) Table 138. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Market Share by Country (2021-2026) Table 139. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032) & (K Units) Table 140. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Market Share Forecast by Country (2027-2032) Table 141. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026) & (US$ Million) Table 143. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Share by Country (2021-2026) Table 144. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Share Forecast by Country (2027-2032) Table 146. Key Raw Materials Table 147. Raw Materials Key Suppliers Table 148. Targeted PSMA Radionuclide Drug Conjugates Distributors List Table 149. Targeted PSMA Radionuclide Drug Conjugates Customers List Table 150. Research Programs/Design for This Report Table 151. Authors List of This Report Table 152. Secondary Sources Table 153. Primary Sources List of Figures Figure 1. Targeted PSMA Radionuclide Drug Conjugates Image Figure 2. Global Targeted PSMA Radionuclide Drug Conjugates Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeted PSMA Radionuclide Drug Conjugates Market Size (2021-2032) & (US$ Million) Figure 4. Global Targeted PSMA Radionuclide Drug Conjugates Sales (2021-2032) & (K Units) Figure 5. Diagnostic Image Figure 6. Global Diagnostic Sales YoY Growth (2021-2032) & (K Units) Figure 7. Therapeutic Image Figure 8. Global Therapeutic Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Targeted PSMA Radionuclide Drug Conjugates Market Share by Type 2025 VS 2032 Figure 11. North America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Type in 2025 Figure 12. North America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Type in 2025 Figure 13. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Type in 2025 Figure 14. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Type in 2025 Figure 17. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Targeted PSMA Radionuclide Drug Conjugates Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Image Figure 24. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 25. Specialist Clinic Image Figure 26. Global Specialist Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 27. Other Image Figure 28. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Targeted PSMA Radionuclide Drug Conjugates Market Share by Application 2025 VS 2032 Figure 31. North America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Application in 2025 Figure 32. North America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Application in 2025 Figure 33. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Application in 2025 Figure 34. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Application in 2025 Figure 37. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Market Share in Value by Application in 2025 Figure 41. North America Targeted PSMA Radionuclide Drug Conjugates Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Targeted PSMA Radionuclide Drug Conjugates Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Targeted PSMA Radionuclide Drug Conjugates Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Targeted PSMA Radionuclide Drug Conjugates Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Targeted PSMA Radionuclide Drug Conjugates Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Targeted PSMA Radionuclide Drug Conjugates Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Targeted PSMA Radionuclide Drug Conjugates Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Targeted PSMA Radionuclide Drug Conjugates Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Targeted PSMA Radionuclide Drug Conjugates Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic
  • Therapeutic
Applications
  • Hospital
  • Specialist Clinic
  • Other
Companies covered
  • Grand Pharmaceutical
  • Novartis
  • University of California
  • Telix Pharmaceutical
  • Lantheus

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Targeted PSMA Radionuclide Drug Conjugates Market by Type
  6. 1.3.1 Diagnostic
  7. 1.3.2 Therapeutic
  8. 1.4 Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Type
  9. 1.4.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Targeted PSMA Radionuclide Drug Conjugates Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Targeted PSMA Radionuclide Drug Conjugates Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Targeted PSMA Radionuclide Drug Conjugates Industry Trends
  2. 2.2 Targeted PSMA Radionuclide Drug Conjugates Industry Drivers
  3. 2.3 Targeted PSMA Radionuclide Drug Conjugates Industry Opportunities and Challenges
  4. 2.4 Targeted PSMA Radionuclide Drug Conjugates Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Targeted PSMA Radionuclide Drug Conjugates Revenue (2021-2026)
  2. 3.2 Global Top Players by Targeted PSMA Radionuclide Drug Conjugates Sales (2021-2026)
  3. 3.3 Global Top Players by Targeted PSMA Radionuclide Drug Conjugates Price (2021-2026)
  4. 3.4 Global Targeted PSMA Radionuclide Drug Conjugates Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Targeted PSMA Radionuclide Drug Conjugates Major Company Production Sites & Headquarters
  6. 3.6 Global Targeted PSMA Radionuclide Drug Conjugates Company, Product Type & Application
  7. 3.7 Global Targeted PSMA Radionuclide Drug Conjugates Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Targeted PSMA Radionuclide Drug Conjugates Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Targeted PSMA Radionuclide Drug Conjugates Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Targeted PSMA Radionuclide Drug Conjugates Tier 1, Tier 2, and Tier 3
4 Targeted PSMA Radionuclide Drug Conjugates Regional Status and Outlook
  1. 4.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Targeted PSMA Radionuclide Drug Conjugates Historic Market Size by Region
  3. 4.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Targeted PSMA Radionuclide Drug Conjugates Forecasted Market Size by Region
  7. 4.3.1 Global Targeted PSMA Radionuclide Drug Conjugates Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Targeted PSMA Radionuclide Drug Conjugates Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Targeted PSMA Radionuclide Drug Conjugates Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Targeted PSMA Radionuclide Drug Conjugates by Application
  1. 5.1 Targeted PSMA Radionuclide Drug Conjugates Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Specialist Clinic
  4. 5.1.3 Other
  5. 5.2 Global Targeted PSMA Radionuclide Drug Conjugates Market Size by Application
  6. 5.2.1 Global Targeted PSMA Radionuclide Drug Conjugates Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Targeted PSMA Radionuclide Drug Conjugates Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Targeted PSMA Radionuclide Drug Conjugates Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Grand Pharmaceutical
  2. 6.1.1 Grand Pharmaceutical Company Information
  3. 6.1.2 Grand Pharmaceutical Business Overview
  4. 6.1.3 Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Grand Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  6. 6.1.5 Grand Pharmaceutical Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 University of California
  14. 6.3.1 University of California Company Information
  15. 6.3.2 University of California Business Overview
  16. 6.3.3 University of California Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 University of California Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  18. 6.3.5 University of California Recent Developments
  19. 6.4 Telix Pharmaceutical
  20. 6.4.1 Telix Pharmaceutical Company Information
  21. 6.4.2 Telix Pharmaceutical Business Overview
  22. 6.4.3 Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Telix Pharmaceutical Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  24. 6.4.5 Telix Pharmaceutical Recent Developments
  25. 6.5 Lantheus
  26. 6.5.1 Lantheus Company Information
  27. 6.5.2 Lantheus Business Overview
  28. 6.5.3 Lantheus Targeted PSMA Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Lantheus Targeted PSMA Radionuclide Drug Conjugates Product Portfolio
  30. 6.5.5 Lantheus Recent Developments
7 North America by Country
  1. 7.1 North America Targeted PSMA Radionuclide Drug Conjugates Sales by Country
  2. 7.1.1 North America Targeted PSMA Radionuclide Drug Conjugates Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026)
  4. 7.1.3 North America Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032)
  5. 7.2 North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
  6. 7.2.1 North America Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026)
  8. 7.2.3 North America Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Country
  2. 8.1.1 Europe Targeted PSMA Radionuclide Drug Conjugates Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026)
  4. 8.1.3 Europe Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
  6. 8.2.1 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026)
  8. 8.2.3 Europe Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Country
  2. 9.1.1 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
  6. 9.2.1 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Targeted PSMA Radionuclide Drug Conjugates Sales by Country
  2. 10.1.1 South America Targeted PSMA Radionuclide Drug Conjugates Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026)
  4. 10.1.3 South America Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032)
  5. 10.2 South America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
  6. 10.2.1 South America Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026)
  8. 10.2.3 South America Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Country
  2. 11.1.1 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Country
  6. 11.2.1 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Targeted PSMA Radionuclide Drug Conjugates Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Targeted PSMA Radionuclide Drug Conjugates Value Chain Analysis
  2. 12.1.1 Targeted PSMA Radionuclide Drug Conjugates Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Targeted PSMA Radionuclide Drug Conjugates Production Mode & Process
  7. 12.2 Targeted PSMA Radionuclide Drug Conjugates Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Targeted PSMA Radionuclide Drug Conjugates Distributors
  10. 12.2.3 Targeted PSMA Radionuclide Drug Conjugates Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst